scholarly journals Successful clozapine re-challenge in a case of Atypical Neuroleptic Malignant Syndrome with markedly elevated Creatinine Phosphokinase and no muscle rigidity

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Ritvij M. Satodiya ◽  
Nikhil J. Palekar
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Muscle Rigidity ◽  
Atypical Neuroleptic ◽  
Elevated Creatinine

Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection

2016 ◽  
Vol 36 (3) ◽  
pp. 277-279 ◽  
Author(s):  
Michael Langley-DeGroot ◽  
Yash Joshi ◽  
David Lehman ◽  
Sanjai Rao
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Atypical Neuroleptic ◽  
Long Acting

Aripiprazole and Atypical Neuroleptic Malignant Syndrome

2004 ◽  
Vol 43 (12) ◽  
pp. 1457-1458 ◽  
Author(s):  
Scott Spalding ◽  
Norman E Alessi ◽  
Karam Radwan
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Atypical Neuroleptic

Neuroleptic Malignant Syndrome – A medical emergency in a psychiatric patient

2018 ◽  
Vol 6 (2) ◽  
pp. 108-110
Author(s):  
Rajib Ahsan Sumon ◽  
Eshita Majumder
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Complete Resolution ◽  
Antipsychotic Drugs ◽  
Medical Emergency ◽  
Muscle Rigidity ◽  
Atypical Antipsychotic Drug ◽  
Presumptive Diagnosis ◽  
Idiosyncratic Reaction ◽  
High Fatality Rate ◽  
Work Up

With an estimated incidence of 0.02 to 3.23%1, neuroleptic malignant syndrome (NMS) is a rare idiosyncratic reaction to antipsychotic drugs; having a relatively high fatality rate of about 10%2. Here, we are reporting, a 38 years old female schizoaffective patient, presented with fever, muscle rigidity and altered sensorium who had started tablet risperidone(an atypical antipsychotic drug) 11 days prior to hospital admission. After initial sepsis work up and neuroimaging, infective causes and acute cerebrovascular incidents were ruled out and a presumptive diagnosis of NMS was made. Immediate discontinuation of suspected causative agent, along with the provision of supportive care leads to complete resolution of all the symptoms in our patient.Bangladesh Crit Care J September 2018; 6(2): 108-110

Atypical neuroleptic malignant syndrome: A systematic review of case reports

2019 ◽  
Vol 60 ◽  
pp. 12-19 ◽  
Author(s):  
Kartik Singhai ◽  
Pooja Patnaik Kuppili ◽  
Naresh Nebhinani
Keyword(s):  
Systematic Review ◽  
Neuroleptic Malignant Syndrome ◽  
Case Reports ◽  
Atypical Neuroleptic

Atypical neuroleptic malignant syndrome associated with Risperidone treatment in two adolescents

2004 ◽  
Vol 16 (2) ◽  
Author(s):  
Gil Zalsman ◽  
Rachel Lewis ◽  
Shai Konas ◽  
Oren Loebstein ◽  
Pablo Goldberg ◽  
...  
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Atypical Neuroleptic ◽  
Risperidone Treatment

On the Early Recognition of Neuroleptic Malignant Syndrome

1986 ◽  
Vol 15 (4) ◽  
pp. 299-310 ◽  
Author(s):  
Terri Clark ◽  
Jambur Ananth ◽  
Stephen Dubin
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Clinical Picture ◽  
Early Recognition ◽  
Neuroleptic Drug ◽  
Altered Consciousness ◽  
Fatal Complication ◽  
Laboratory Findings ◽  
Autonomic Instability ◽  
Elevated Creatinine

Neuroleptic Malignant Syndrome, a serious and sometimes fatal complication, has been reported to occur in some patients with the administration of neuroleptic medications. Clinically it is manifested by four groups of symptoms which include muscular hypertonicity, autonomic instability, altered consciousness, and hyperthermia. Laboratory findings such as elevated creatinine phosphokinase and leukocytosis are also seen. While it is true that the incidence of the full blown clinical picture of this syndrome is rare, the authors report that only muscular hypertonicity and autonomic instability have occurred frequently in their setting leading to discontinuation of neuroleptics. Such abortive cases may go undetected. If properly diagnosed, the occurrence of this syndrome is not as rare as the published reports indicate. Second, it is reported that rechallenge with neuroleptics may not induce Neuroleptic Malignant Syndrome again. The authors noted recurrence of fever after rechallenge with a different neuroleptic drug. This article describes the method of early recognition and prevention of morbidity as well as mortality.

Risperidone-Induced Neuroleptic Malignant Syndrome

1996 ◽  
Vol 30 (7-8) ◽  
pp. 775-778 ◽  
Author(s):  
Roopali Sharma ◽  
Brian Trappler ◽  
Yiu Kee Ng ◽  
Cavin P Leeman
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Medical Records ◽  
Altered Mental Status ◽  
Resident Physician ◽  
Muscle Rigidity ◽  
Data Synthesis ◽  
Unsuccessful Treatment ◽  
Data Source ◽  
Prolonged Hospital ◽  
Supportive Management

OBJECTIVE: To describe a patient with neuroleptic malignant syndrome (NMS) induced by risperidone, an atypical antipsychotic, and to review the available literature related to risperidone-associated NMS. DATA SOURCE: Case report information was obtained from the resident physician and medical records. MEDLINE and Index Medicus were searched to obtain literature published between 1960 and 1995. DATA SYNTHESIS: We report an adolescent boy who developed NMS after treatment with risperidone. Risperidone therapy was started after unsuccessful treatment and development of extrapyramidal adverse effects with haloperidol. The patient demonstrated the classic tetrad of fever, generalized skeletal muscle rigidity, altered mental status, and autonomic dysfunction. Risperidone was discontinued and the patient recovered after a prolonged hospital course with supportive management. CONCLUSIONS: Clinicians are cautioned about the possibility of NMS with risperidone.

scholarly journals Atypical Neuroleptic Malignant Syndrome Caused by Clozapine and Venlafaxine: Early Brief Treatment with Dantrolene

2004 ◽  
Vol 49 (7) ◽  
pp. 497-498 ◽  
Author(s):  
Vittorio Ferioli ◽  
Allesandra Manes ◽  
Chiara Melloni ◽  
Samuele Nanni ◽  
Giancarlo Boncompagni
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Brief Treatment ◽  
Atypical Neuroleptic
Sign in / Sign up

Export Citation Format

Share Document